One of my primary research interests is in the development, validation, and analysis of patient relevant outcome measures for use in drug labeling trials. Current work from my laboratory involves the development of disease-specific, relevant, valid, responsive, reliable, clinical trial instruments for myotonic dystrophy type-1 (DM1), myotonic dystrophy type-2 (DM2), congenital myotonic dystrophy (CMD), juvenile myotonic dystrophy (JMD), Charcot-Marie Tooth 1a (CMT1a), inclusion body myositis (IBM), and facioscapulohumeral muscular dystrophy (FSHD).